BBA
SRPT icon

BLB&B Advisors’s Sarepta Therapeutics SRPT Stock Holding History

BLB&B Advisors’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-3,000
Closed -$511K – 265
2020
Q4 		$511K Buy
+3,000
New +$445K 0.04% 170

Other funds holding SRPT

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

BLB&B Advisors's SRPT Position: Q1 2021 in Review

BLB&B Advisors sold out of Sarepta Therapeutics (SRPT) in Q1 2021, closing a stake of 3,000 shares — an estimated $511K sold.

BLB&B Advisors first reported a position in SRPT in Q4 2020 and held it in 1 quarter. The position peaked at $511K in Q4 2020. 366 funds tracked by Wall St. Rank hold SRPT as of Q1 2021.

  • BLB&B Advisors reported no remaining Sarepta Therapeutics position as of Q1 2021 after selling out during the quarter.
  • BLB&B Advisors sold 3,000 Sarepta Therapeutics shares in Q1 2021, an estimated $511K.
  • BLB&B Advisors first reported a position in Sarepta Therapeutics in Q4 2020 and held it in 1 quarter.
  • BLB&B Advisors's Sarepta Therapeutics position peaked at $511K in Q4 2020.
  • 366 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q1 2021.

Based on BLB&B Advisors's 13F filing for Q1 2021, filed 19 Apr 2021.